- Home
- SILC vs CLRB Comparison
SILC vs CLRB Comparison
Compare SILC & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILC
- CLRB
- Stock Information
- Founded
- SILC 1987
- CLRB 2002
- Country
- SILC Israel
- CLRB United States
- Employees
- SILC N/A
- CLRB N/A
- Industry
- SILC Computer Manufacturing
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- SILC Technology
- CLRB Health Care
- Exchange
- SILC Nasdaq
- CLRB Nasdaq
- Market Cap
- SILC 86.9M
- CLRB 76.0M
- IPO Year
- SILC 1994
- CLRB N/A
- Fundamental
- Price
- SILC $14.23
- CLRB $1.86
- Analyst Decision
- SILC Hold
- CLRB Strong Buy
- Analyst Count
- SILC 1
- CLRB 2
- Target Price
- SILC N/A
- CLRB $21.00
- AVG Volume (30 Days)
- SILC 11.5K
- CLRB 289.0K
- Earning Date
- SILC 10-31-2024
- CLRB 11-18-2024
- Dividend Yield
- SILC N/A
- CLRB N/A
- EPS Growth
- SILC N/A
- CLRB N/A
- EPS
- SILC N/A
- CLRB N/A
- Revenue
- SILC $62,386,000.00
- CLRB N/A
- Revenue This Year
- SILC N/A
- CLRB N/A
- Revenue Next Year
- SILC $4.15
- CLRB N/A
- P/E Ratio
- SILC N/A
- CLRB N/A
- Revenue Growth
- SILC N/A
- CLRB N/A
- 52 Week Low
- SILC $11.35
- CLRB $1.82
- 52 Week High
- SILC $19.04
- CLRB $4.45
- Technical
- Relative Strength Index (RSI)
- SILC 55.56
- CLRB 30.70
- Support Level
- SILC $13.75
- CLRB $1.97
- Resistance Level
- SILC $14.55
- CLRB $2.18
- Average True Range (ATR)
- SILC 0.52
- CLRB 0.10
- MACD
- SILC 0.03
- CLRB -0.01
- Stochastic Oscillator
- SILC 65.91
- CLRB 8.11
About SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters; Edge Networking Solutions; FPGA Based Cards; x86 Open Appliances Bypass Switches and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.